» Articles » PMID: 32901360

Identification of Novel Candidate Genes by Exome Sequencing in Tunisian Familial Male Breast Cancer Patients

Overview
Journal Mol Biol Rep
Specialty Molecular Biology
Date 2020 Sep 9
PMID 32901360
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Male Breast Cancer (MBC) is a rare and aggressive disease that is associated with genetic factors. Mutations in BRCA1 and BRCA2 account for 10% of all MBC cases suggesting that other genetic factors are involved. The aim of the present study is to screen whole BRCA1 and BRCA2 exons using the Ampliseq BRCA panel in Tunisian MBC patients with family history. Furthermore, we performed exome sequencing using the TruSight One sequencing panel on an early onset BRCA negative patient. We showed that among the 6 MBC patients, only one (MBC-F1) harbored a novel frameshift mutation in exon 2 of the BRCA2 gene (c.17-20delAAGA, p.Lys6Xfs) resulting in a short BRCA2 protein of only 6 amino-acids. We selected 9 rare variants after applying several filter steps on the exome sequencing data. Among these variants, and based on their role in breast carcinogenesis, we retained 6 candidate genes (MSH5, DCC, ERBB3, NOTCH3, DIAPH1, and DNAH11). Further studies are needed to confirm the association of the selected genes with family MBC.

Citing Articles

Is Tunisia ready for precision medicine? Challenges of medical genomics within a LMIC healthcare system.

Trabelsi N, Othman H, Bedhioufi H, Chouk H, El Mabrouk H, Mahdouani M J Community Genet. 2024; 15(4):339-350.

PMID: 39080231 PMC: 11411033. DOI: 10.1007/s12687-024-00722-x.


Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients.

Al Saati A, Vande Perre P, Plenecassagnes J, Gilhodes J, Monselet N, Cabarrou B Int J Mol Sci. 2023; 24(18).

PMID: 37762649 PMC: 10531866. DOI: 10.3390/ijms241814348.


Identification of Eleven Novel Mutations in Tunisia: Impact on the Clinical Management of Related Cancers.

Hamdi Y, Mighri N, Boujemaa M, Mejri N, Ben Nasr S, Ben Rekaya M Front Oncol. 2021; 11:674965.

PMID: 34490083 PMC: 8417726. DOI: 10.3389/fonc.2021.674965.

References
1.
Speirs V, Shaaban A . The rising incidence of male breast cancer. Breast Cancer Res Treat. 2008; 115(2):429-30. DOI: 10.1007/s10549-008-0053-y. View

2.
Ruddy K, Winer E . Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol. 2013; 24(6):1434-43. DOI: 10.1093/annonc/mdt025. View

3.
Deb S, Lakhani S, Ottini L, Fox S . The cancer genetics and pathology of male breast cancer. Histopathology. 2016; 68(1):110-8. DOI: 10.1111/his.12862. View

4.
Frank T, Deffenbaugh A, Reid J, Hulick M, Ward B, Lingenfelter B . Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002; 20(6):1480-90. DOI: 10.1200/JCO.2002.20.6.1480. View

5.
Zheng G, Yu H, Hemminki A, Forsti A, Sundquist K, Hemminki K . Familial associations of female breast cancer with other cancers. Int J Cancer. 2017; 141(11):2253-2259. DOI: 10.1002/ijc.30927. View